Study: NCT02604212

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: entecavir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: antihistamine
Description: All participants will be pretreated with an oral antihistamine. The antihistamine used should in general be an H1\>H2 receptor blocker and would include diphenhydramine 50 mg, cetirizine 10 mg, chlorpheniramine 8 mg or hydroxyzine 50 mg. The Investigator is free to choose any of these antihistamines available locally and consistent with their country's Marketing Authorisation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir
Description: All participants will take entecavir or tenofovir throughout the study. Participants will be instructed to take their medication daily.